Modifying an obesity drug could reduce side effects like anxiety and depression

April 28, 2016, Elsevier

A new version of an obesity drug that caused serious psychiatric side effects could help people lose pounds without experiencing the anxiety, depression and suicidal thoughts previously associated with it. The research, published in Bioorganic and Medicinal Chemistry, shows that the new version of the drug can still work without reaching the brain in rats, avoiding the side effects.

The researchers behind the study, from RTI International in the US, say this means the new version of the could be used in the future for treating obesity. And their approach could also support the development of drugs to tackle liver disease, and .

In our bodies we have that control appetite, mood, memory and pain. The obesity drug Rimonabant stops these receptors from working. But the drug was found to have serious psychiatric side effects in a small number of the people who took it. Because of this, the drug was never approved in the US and manufacturer Sanofi-Aventis pulled from the European market voluntarily.

In the new study, the researchers altered the drug so it no longer gets into the brain, which stops it from having psychiatric side effects.

Study author Dr. Rangan Maitra, from RTI International in the US, explained: "There is a real need for new medicines to treat metabolic conditions like obesity. We are working with chemists to alter the drug Rimonabant and create compounds that cannot get into the brain. We hope this will help create drugs that can treat people with these conditions, without them having to suffer the ."

Dr. Maitra and colleagues modified the original Rimonabant compound by changing its weight, polarity and other properties to try to stop it from getting into the brain.

Tests in rats found that one of the versions, called 8c, blocks the target receptor and is much less likely than the original drug to get into the brain and affect the central nervous system.

The researchers found that 8c mostly stays in the blood and works on cannabinoid receptors found in parts of the body other than the brain. In comparison, more than half of the original drug Rimonabant entered the brain.

It's early days for the research, and the new version of the drug will need to go through testing before it can be used to treat people, but the researchers say it's a step in the right direction. Their study also outlines how scientists can test drugs designed to target cannabinoid receptors to make sure they are working outside the brain.

"Drug development is a long and arduous process," said Dr. George Amato, co-author of the study. "You have to develop hundreds, if not thousands, of compounds before you get the right one. The challenge is that some medicines that are absorbed in the gut also get into the brain. We set out to find compounds that absorb across the gut barrier but not the barrier. We've identified some, and they'll now serve as lead structures for further refinement."

Explore further: New drug could help maintain long-term weight loss

More information: Alan Fulp et al, Pyrazole antagonists of the CB1 receptor with reduced brain penetration, Bioorganic & Medicinal Chemistry (2016). DOI: 10.1016/j.bmc.2016.01.033

Related Stories

New drug could help maintain long-term weight loss

July 26, 2012
A new drug could aid in losing weight and keeping it off. The drug, described in the journal Cell Metabolism on July 26, increases sensitivity to the hormone leptin, a natural appetite suppressant found in the body. Although ...

Common cholesterol drug stimulates the same receptors as marijuana

April 1, 2015
If you want the benefits of medical marijuana without the "unwanted side effects" of cannabis, new research should leave you on a high note. According to a research report appearing in the April 2015 issue of The FASEB Journal, ...

Recommended for you

Bursts of brain activity linked to memory reactivation

May 24, 2018
Leading theories propose that sleep presents an opportune time for important, new memories to become stabilized. And it's long been known which brain waves are produced during sleep. But in a new study, researchers set out ...

Study suggests brainwave link between disparate disorders

May 24, 2018
A brainwave abnormality could be a common link between Parkinson's disease, neuropathic pain, tinnitus and depression—a link that authors of a new study suggest could lead to treatment for all four conditions.

Researchers define molecular basis to explain link between a pregnant mother's nutrition and infant growth

May 24, 2018
For years, pregnant mothers have questioned their nutritional habits: "Will eating more cause my baby to be overweight?" Or, "I'm eating for two, so it won't hurt to have an extra serving, right?"

In a break with dogma, myelin boosts neuron growth in spinal cord injuries

May 23, 2018
Recovery after severe spinal cord injury is notoriously fraught, with permanent paralysis often the result. In recent years, researchers have increasingly turned to stem cell-based therapies as a potential method for repairing ...

Memory molecule limits plasticity by calibrating calcium

May 23, 2018
The brain has an incredible capacity to support a lifetime of learning and memory. Each new experience fundamentally alters the connections between cells in the brain called synapses. To accommodate synaptic alterations, ...

New type of vertigo identified

May 23, 2018
Neurologists have identified a new type of vertigo with no known cause, according to a study published in the May 23, 2018, online issue of Neurology, the medical journal of the American Academy of Neurology.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.